Emblem Cannabis Corporation, a wholly-owned subsidiary of Red White & Bloom Brands (CSE: RWB), is set to complete its acquisition of insolvent Canadian cannabis company Ayurcann on or about 5 June 2026, picking up a Health Canada-licensed manufacturing facility, three consumer brands, and distribution across eight Canadian provinces for an undisclosed cash sum.
The closing brings to an end a CCAA process, Canada’s court-supervised insolvency framework, that began on 30 January 2026, when Ayurcann filed for creditor protection under acute pressure from the Canada Revenue Agency.
The company’s court filings record a liquidity crisis and approximately CA$10.6m owed to the CRA in outstanding taxes, interest and penalties as of 26 January 2026.
Founded in 2018, Ayurcann had grown from a B2B cannabis services provider into a vertically integrated operator with its own brands and a licensed processing and manufacturing facility in Pickering, Ontario, but could not absorb the cost of federally licensed manufacturing against continued wholesale price compression in the adult-use market.
The Ontario Superior Court approved a formal sale process on 13 February 2026. Emblem was selected as the winning bidder on 13 April, with closing scheduled no later than 30 June.
BofC Intelligence Cannabis M&A Tracker Tracking mergers, acquisitions and major deals shaping the global cannabis industry since 2020. Updated regularly by the Business of Cannabis editorial team.
Explore Now →
Emblem’s soon-to-be-acquired portfolio includes the Fuego, Xplor and Happy & Stoned labels, approximately 146 product lines distributed across around 2,600 retail outlets in eight provinces and territories, with vapes and pre-rolls at the core.
Beyond IP, Ayurcann’s Pickering facility, production equipment, intellectual property and existing commercial relationships will be transferred as part of the deal. Emblem will acquire 100% of newly issued Ayurcann shares, holding the operating business and its regulatory licences indirectly.
On 2 June, Emblem assumed bridge financing previously provided by Auxly Cannabis Group, paying CA$1.6m to acquire Auxly’s outstanding loan and related security interests. Auxly, which had provided that financing since February, exited its creditor position on the same date. Emblem has simultaneously committed a new CA$3m loan facility at 12% per annum to fund Ayurcann’s operations through to closing.
For RWB, the deal deepens a Canadian manufacturing platform it only recently acquired. The company entered the Canadian market in January 2024 through its acquisition of Aleafia Health for approximately CA$31.7m, a deal that brought Emblem Cannabis into the group along with a 65,000 sq ft EU-GMP facility in Paris, Ontario and distribution into five Canadian provinces, plus medical and international channels.
Emblem already holds a Canadian cannabis processing licence, but the Pickering facility adds a more substantial production platform and Ayurcann’s distribution relationships across three additional provinces.
The post Emblem Cannabis Set to Complete Acquisition of Ayurcann Assets, Adding Vape and Pre-Roll Manufacturing to Portfolio appeared first on Business of Cannabis.
Continue reading...
The closing brings to an end a CCAA process, Canada’s court-supervised insolvency framework, that began on 30 January 2026, when Ayurcann filed for creditor protection under acute pressure from the Canada Revenue Agency.
The company’s court filings record a liquidity crisis and approximately CA$10.6m owed to the CRA in outstanding taxes, interest and penalties as of 26 January 2026.
Founded in 2018, Ayurcann had grown from a B2B cannabis services provider into a vertically integrated operator with its own brands and a licensed processing and manufacturing facility in Pickering, Ontario, but could not absorb the cost of federally licensed manufacturing against continued wholesale price compression in the adult-use market.
The Ontario Superior Court approved a formal sale process on 13 February 2026. Emblem was selected as the winning bidder on 13 April, with closing scheduled no later than 30 June.
BofC Intelligence Cannabis M&A Tracker Tracking mergers, acquisitions and major deals shaping the global cannabis industry since 2020. Updated regularly by the Business of Cannabis editorial team.
Explore Now →
Emblem’s soon-to-be-acquired portfolio includes the Fuego, Xplor and Happy & Stoned labels, approximately 146 product lines distributed across around 2,600 retail outlets in eight provinces and territories, with vapes and pre-rolls at the core.
Beyond IP, Ayurcann’s Pickering facility, production equipment, intellectual property and existing commercial relationships will be transferred as part of the deal. Emblem will acquire 100% of newly issued Ayurcann shares, holding the operating business and its regulatory licences indirectly.
On 2 June, Emblem assumed bridge financing previously provided by Auxly Cannabis Group, paying CA$1.6m to acquire Auxly’s outstanding loan and related security interests. Auxly, which had provided that financing since February, exited its creditor position on the same date. Emblem has simultaneously committed a new CA$3m loan facility at 12% per annum to fund Ayurcann’s operations through to closing.
For RWB, the deal deepens a Canadian manufacturing platform it only recently acquired. The company entered the Canadian market in January 2024 through its acquisition of Aleafia Health for approximately CA$31.7m, a deal that brought Emblem Cannabis into the group along with a 65,000 sq ft EU-GMP facility in Paris, Ontario and distribution into five Canadian provinces, plus medical and international channels.
Emblem already holds a Canadian cannabis processing licence, but the Pickering facility adds a more substantial production platform and Ayurcann’s distribution relationships across three additional provinces.
The post Emblem Cannabis Set to Complete Acquisition of Ayurcann Assets, Adding Vape and Pre-Roll Manufacturing to Portfolio appeared first on Business of Cannabis.
Continue reading...
